{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T14:34:33Z","timestamp":1775918073063,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K23 AI110532"],"award-info":[{"award-number":["K23 AI110532"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 DK126042"],"award-info":[{"award-number":["R01 DK126042"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Principal Investigator"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cardiometabolic disease in transgender women (TW) is affected by gender-affirming hormonal therapies (GAHTs), HIV, and antiretroviral therapy (ART). We evaluated the 48-week safety\/tolerability of switching to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) vs continued ART in TW on GAHT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>TW on GAHT and suppressive ART were randomized 1:1 to switch to B\/F\/TAF (Arm A) or continue current ART (Arm B). Cardiometabolic biomarkers, sex hormones, bone mineral density (BMD) and lean\/fat mass by DXA scan, and hepatic fat (controlled continuation parameter [CAP]) were measured. Wilcoxon rank-sum\/signed-rank and \u03c72 tests compared continuous and categorical variables.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>TW (Arm A n = 12, Arm B n = 9) had a median age of 45 years. Ninety-five percent were non-White; 70% were on elvitegravir or dolutegravir, 57% TAF, 24% abacavir, and 19% TDF; 29% had hypertension, 5% diabetes, and 62% dyslipidemia. There were no adverse events. Arm A\/B had 91%\/89% undetectable HIV-1 RNA at week 48 (w48). Baseline (BL) osteopenia (Arm A\/B 42%\/25%) and osteoporosis (17%\/13%) were common, without significant changes. BL lean\/fat mass were similar. At w48, Arm A had stable lean mass but increased limb (3 lbs) and trunk (3 lbs) fat (within-arm P &amp;lt; .05); fat in Arm B remained stable. No changes occurred in lipid or glucose profiles. Arm B had a greater w48 decrease (\u221225 vs \u22123\u2005dB\/m; P = .03) in CAP. BL and w48 concentrations of all biomarkers were similar.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this cohort of TW, switch to B\/F\/TAF was safe and metabolically neutral, though greater fat gain occurred on B\/F\/TAF. Further study is needed to better understand cardiometabolic disease burden in TW with HIV.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad178","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T18:23:14Z","timestamp":1680718994000},"source":"Crossref","is-referenced-by-count":8,"title":["A Randomized Clinical Trial of Transgender Women Switching to B\/F\/TAF: The (mo)BETTA Trial"],"prefix":"10.1093","volume":"10","author":[{"given":"Jordan E","family":"Lake","sequence":"first","affiliation":[{"name":"Department of Medicine, UTHealth Houston , Houston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8041-4331","authenticated-orcid":false,"given":"Ana N","family":"Hyatt","sequence":"additional","affiliation":[{"name":"Department of Medicine, UTHealth Houston , Houston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3163-8931","authenticated-orcid":false,"given":"Han","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, UTHealth School of Public Health , Houston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Debroy","sequence":"additional","affiliation":[{"name":"Department of Medicine, UTHealth Houston , Houston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaren","family":"Kettelhut","sequence":"additional","affiliation":[{"name":"Division of Medical Laboratory Science, The Ohio State University , Columbus, Ohio , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, UTHealth School of Public Health , Houston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital , Boston, Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-6200","authenticated-orcid":false,"given":"Shalender","family":"Bhasin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital , Boston, Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Bell","sequence":"additional","affiliation":[{"name":"Department of Medicine, UTHealth Houston , Houston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahid","family":"Rianon","sequence":"additional","affiliation":[{"name":"Department of Medicine, UTHealth Houston , Houston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd T","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas T","family":"Funderburg","sequence":"additional","affiliation":[{"name":"Division of Medical Laboratory Science, The Ohio State University , Columbus, Ohio , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"2023042214485423100_ofad178-B1","author":"Centers for Disease Control and Prevention"},{"key":"2023042214485423100_ofad178-B2","doi-asserted-by":"crossref","DOI":"10.2105\/AJPH.2018.304727","article-title":"Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006\u20132017","volume":"109","author":"Becasen","year":"2019","journal-title":"Am J Public Health"},{"key":"2023042214485423100_ofad178-B3","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S1473-3099(13)70271-8","article-title":"Metabolic disease in HIV infection","volume":"13","author":"Lake","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2023042214485423100_ofad178-B4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-17-0496","article-title":"Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study","volume":"178","author":"Klaver","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2023042214485423100_ofad178-B5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261312","article-title":"The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis","volume":"17","author":"Schutte","year":"2022","journal-title":"PLoS One"},{"key":"2023042214485423100_ofad178-B6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2023042214485423100_ofad178-B7","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1038\/s41366-021-00935-x","article-title":"Weight gain and obesity rates in transgender and gender-diverse adults before and during hormone therapy","volume":"45","author":"Kyinn","year":"2021","journal-title":"Int J Obes"},{"key":"2023042214485423100_ofad178-B8","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"2023042214485423100_ofad178-B9","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/cid\/ciaa429","article-title":"Optimal threshold of controlled attenuation parameter for detection of HIV-associated NAFLD with magnetic resonance imaging as the reference standard","volume":"72","author":"Ajmera","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023042214485423100_ofad178-B10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/MEG.0000000000000339","article-title":"Hepatic steatosis in individuals living with HIV measured by controlled attenuation parameter: a cross-sectional study","volume":"27","author":"Sulyok","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2023042214485423100_ofad178-B11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11904-016-0298-8","article-title":"Fat matters: understanding the role of adipose tissue in health in HIV infection","volume":"13","author":"Erlandson","year":"2016","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2023042214485423100_ofad178-B12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11904-020-00483-5","article-title":"Obesity and weight gain in persons with HIV","volume":"17","author":"Bailin","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2023042214485423100_ofad178-B13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41572-020-0181-1","article-title":"HIV and antiretroviral therapy-related fat alterations","volume":"6","author":"Koethe","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2023042214485423100_ofad178-B14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","article-title":"Weight gain and integrase inhibitors","volume":"33","author":"Eckard","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2023042214485423100_ofad178-B15","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023042214485423100_ofad178-B16","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2023042214485423100_ofad178-B17","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/jac\/dkz224","article-title":"Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the phase II ANRS 163 ETRAL study","volume":"74","author":"Katlama","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023042214485423100_ofad178-B18","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa177","article-title":"Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy","volume":"71","author":"Lake","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023042214485423100_ofad178-B19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/COH.0000000000000680","article-title":"Impact of integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV","volume":"16","author":"Lake","year":"2021","journal-title":"Curr Opin HIV AIDS"},{"key":"2023042214485423100_ofad178-B20","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/jac\/dky551","article-title":"Progressive increases in fat mass occur in adults living with HIV on antiretroviral therapy, but patterns differ by sex and anatomic depot","volume":"74","author":"Debroy","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023042214485423100_ofad178-B21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/25787489.2020.1848131","article-title":"Changes in central adipose tissue after switching to integrase inhibitors","volume":"21","author":"Debroy","year":"2020","journal-title":"HIV Res Clin Pract"},{"key":"2023042214485423100_ofad178-B22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/cid\/ciz853","article-title":"Weight gain associated with integrase stand transfer inhibitor use in women","volume":"71","author":"Kerchberger","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023042214485423100_ofad178-B23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1089\/aid.2020.0117","article-title":"Short communication: no significant changes in weight and body fat mass in suppressed HIV-infected patients switched to dual combination lamivudine plus dolutegravir or raltegravir","volume":"37","author":"Calza","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023042214485423100_ofad178-B24","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"2023042214485423100_ofad178-B25","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.bone.2008.09.001","article-title":"Body composition, volumetric and areal bone parameters in male-to-female transsexual persons","volume":"43","author":"Lapauw","year":"2008","journal-title":"Bone"},{"key":"2023042214485423100_ofad178-B26","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1111\/j.1743-6109.2012.02876.x","article-title":"Long-term evaluation of cross-sex hormone treatment in transsexual persons","volume":"9","author":"Wierckx","year":"2012","journal-title":"J Sex Med"},{"key":"2023042214485423100_ofad178-B27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ecl.2019.02.006","article-title":"Osteoporosis and bone health in transgender persons","volume":"48","author":"Stevenson","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2023042214485423100_ofad178-B28","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2022.100173","article-title":"The effects of gender-affirming hormone therapy on cardiovascular and skeletal health: a literature review","volume":"13","author":"Chan Swe","year":"2022","journal-title":"Metabol Open"},{"key":"2023042214485423100_ofad178-B29","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1210\/js.2018-00413","article-title":"Bone mass effects of cross-sex hormone therapy in transgender people: updated systematic review and meta-analysis","volume":"3","author":"Fighera","year":"2019","journal-title":"J Endocr Soc"},{"key":"2023042214485423100_ofad178-B30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5312\/wjo.v3.i12.223","article-title":"Male osteoporosis: a review","volume":"3","author":"Herrera","year":"2012","journal-title":"World J Orthop"},{"key":"2023042214485423100_ofad178-B31","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1097\/QAD.0000000000003346","article-title":"Trans women have worse cardiovascular biomarker profiles than cisgender men independent of hormone use and HIV serostatus","volume":"36","author":"Lake","year":"2022","journal-title":"AIDS"},{"key":"2023042214485423100_ofad178-B32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0092-8674(00)80801-6","article-title":"RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100\/calgranulin polypeptides","volume":"97","author":"Hofmann","year":"1999","journal-title":"Cell"},{"key":"2023042214485423100_ofad178-B33","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1164\/rccm.201209-1602OC","article-title":"Proinflammatory S100A12 can activate human monocytes via toll-like receptor 4","volume":"187","author":"Foell","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2023042214485423100_ofad178-B34","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1161\/ATVBAHA.114.304306","article-title":"EN-RAGE: a novel inflammatory marker for incident coronary heart disease","volume":"34","author":"Ligthart","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042214485423100_ofad178-B35","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.653655","article-title":"A serpin with a finger in many PAIs: pAI-1's central function in thromboinflammation and cardiovascular disease","volume":"8","author":"Morrow","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2023042214485423100_ofad178-B36","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1097\/QAD.0000000000000247","article-title":"Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals","volume":"28","author":"Knudsen","year":"2014","journal-title":"AIDS"},{"key":"2023042214485423100_ofad178-B37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1089\/aid.2016.0292","article-title":"Plasminogen activator inhibitor-1 predicts negative alterations in whole-body insulin sensitivity in chronic HIV infection","volume":"33","author":"Wirunsawanya","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023042214485423100_ofad178-B38","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/cen.13800","article-title":"High irisin levels in nondiabetic HIV-infected males are associated with insulin resistance, nonalcoholic fatty liver disease, and subclinical atherosclerosis","volume":"89","author":"Moreno-Perez","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023042214485423100_ofad178-B39","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2020.07.044","article-title":"Sex-specific associations of cardiovascular risk factors and biomarkers with incident heart failure","volume":"76","author":"Suthahar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023042214485423100_ofad178-B40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/13685530701653538","article-title":"Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes","volume":"10","author":"Haidar","year":"2007","journal-title":"Aging Male"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad178\/49771747\/ofad178.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/4\/ofad178\/50066137\/ofad178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/4\/ofad178\/50066137\/ofad178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T14:49:29Z","timestamp":1682174969000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad178\/7109150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad178","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,4,1]]},"article-number":"ofad178"}}